Top

Published in:

01-10-2017 | Original Article

Cardiovascular effect of inflammation and nonsteroidal anti-inflammatory drugs on renin–angiotensin system in experimental arthritis

Authors: Waheed Asghar, Ali Aghazadeh-Habashi, Fakhreddin Jamali

Published in: Inflammopharmacology | Issue 5/2017

Abstract

A co-morbidity of inflammatory conditions is increased cardio-renal risks. Additionally, nonsteroidal anti-inflammatory drugs (NSAIDs) which are used to treat pain and inflammation are also associated with increase in such risks. We hypothesized that inflammation and NSAIDs impose the cardio-renal risk through the activation of the renin-angiotensin-system (RAS), a regulating pathway of the renal and cardiovascular homeostasis. We investigated the effect of adjuvant arthritis and NSAIDs on the RAS. Western blotting and ELISA were used to measure the RAS components. Inflammation caused significant imbalances in the cardiac and renal angiotensin converting enzymes, their biologically active angiotensin peptides (AngII and Ang1-7) and the target proteins involved in the peptide-receptor binding (AngII type 1 and type 2, and Ang1-7 receptor, Mas) toward cardio-renal toxicity. However, 7 days treatment of arthritic animals with NSAIDs (rofecoxib, meloxicam, celecoxib and flurbiprofen) restored the constitutive balances, perhaps due to their anti-inflammatory properties. Inflammation exerts its cardio-renal effects by causing imbalance in the RAS. NSAIDs through their anti-inflammatory effect restore this imbalance. Thus, mechanisms other than imbalances in the RAS may be involved in the NSAIDs cardiotoxicity.

Aghazadeh-Habashi A, Kohan MH, Asghar W, Jamali F (2014) Glucosamine dose/concentration-effect correlation in the rat with adjuvant arthritis. J Pharm Sci 103:760–767CrossRefPubMed

Arfe A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B et al (2016) Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case–control study. BMJ 354:i4857CrossRefPubMed

Asghar W, Jamali F (2015) The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology 23:1–16CrossRefPubMed

Balcells E, Meng QC, Johnson WH, Jr, Oparil S, Dell'Italia LJ (1997) Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 273:H1769–H1774PubMed

Davies NM, Jamali F (2004) COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Pharm Sci 7:332–336PubMed

Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N et al (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87:E1–E9CrossRefPubMed

e Simoes Silva AC, Silveira KD, Ferreira AJ, Teixeira MM (2013) ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol 169:477–492CrossRef

Filho AG, Ferreira AJ, Santos SH, Neves SR, Silva Camargos ER, Becker LK et al (2008) Selective increase of angiotensin(1-7) and its receptor in hearts of spontaneously hypertensive rats subjected to physical training. Exp Physiol 93:589–598PubMed

Firth JD, Uitto VJ, Putnins EE (2008) Mechanical induction of an epithelial cell chymase associated with wound edge migration. J Biol Chem 283:34983–34993CrossRefPubMedPubMedCentral

Gao L, Wang WZ, Wang W, Zucker IH (2008) Imbalance of angiotensin type 1 receptor and angiotensin II type 2 receptor in the rostral ventrolateral medulla: potential mechanism for sympathetic overactivity in heart failure. Hypertension 52:708–714CrossRefPubMedPubMedCentral

Gross GJ, Hsu A, Falck JR, Nithipatikom K (2007) Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J Mol Cell Cardiol 42:687–691CrossRefPubMedPubMedCentral

Guirguis MS, Jamali F (2003) Disease–drug interaction: reduced response to propranolol despite increased concentration in the rat with inflammation. J Pharm Sci 92:1077–1084CrossRefPubMed

Hanafy S, Tavasoli M, Jamali F (2011) Inflammation alters angiotensin converting enzymes (ACE and ACE-2) balance in rat heart. Inflammation 34:609–613CrossRefPubMed

Hanafy S, El-Kadi AO, Jamali F (2012) Effect of inflammation on molecular targets and drug transporters. J Pharm Pharm Sci 15:361–375CrossRefPubMed

Harirforoosh S, Aghazadeh-Habashi A, Jamali F (2006) Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent. Clin Exp Pharmacol Physiol 33:917–924CrossRefPubMed

Harirforoosh S, Asghar W, Jamali F (2013) Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci 16:821–847CrossRefPubMed

Karpati P (2005) The role of ACE inhibitors and angiotensin receptor blockers in the treatment and prevention of chronic heart failure. Orv Hetil 146:827–831PubMed

Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F et al (2008) Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 118:2523–2532CrossRefPubMed

Kim S, Iwao H (2000) Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52:11–34PubMed

Kleber FX, Baumann G (1993) Significance of treatment of early forms and prevention of heart failure. Value of ACE inhibitors in therapy after myocardial infarct. Acta Med Austriaca 20:95–99PubMed

Kulmatycki KM, Jamali F (2001) Therapeutic relevance of altered cytokine expression. Cytokine 14:1–10CrossRefPubMed

Kulmatycki KM, Abouchehade K, Sattari S, Jamali F (2001) Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat. Br J Pharmacol 133:286–294CrossRefPubMedPubMedCentral

Ling S, Lewanczuk RZ, Russell AS, Ihejirika B, Jamali F (2009) Influence of controlled rheumatoid arthritis on the action and disposition of verapamil: focus on infliximab. J Clin Pharmacol 49:301–311CrossRefPubMed

Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52:722–732CrossRefPubMed

Mayo PR, Skeith K, Russell AS, Jamali F (2000) Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br J Clin Pharmacol 50:605–613CrossRefPubMedPubMedCentral

Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K et al (1997) Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 96:3954–3962CrossRefPubMed

Parajuli N, Ramprasath T, Patel VB, Wang W, Putko B, Mori J et al (2014) Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases. Can J Physiol Pharmacol 92:558–565CrossRefPubMed

Patel VB, Zhong JC, Fan D, Basu R, Morton JS, Parajuli N et al (2014) Angiotensin-converting enzyme 2 is a critical determinant of angiotensin II-induced loss of vascular smooth muscle cells and adverse vascular remodeling. Hypertension 64:157–164CrossRefPubMed

Rainsford KD (1982) Adjuvant polyarthritis in rats: is this a satisfactory model for screening anti-arthritic drugs? Agents Actions 12:452–458CrossRefPubMed

Rompe F, Artuc M, Hallberg A, Alterman M, Stroder K, Thone-Reineke C et al (2010) Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 55:924–931CrossRefPubMed

Sanaee F, Clements JD, Waugh AW, Fedorak RN, Lewanczuk R, Jamali F (2011) Drug-disease interaction: Crohn’s disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity. Br J Clin Pharmacol 72:787–797CrossRefPubMedPubMedCentral

Sattari S, Dryden WF, Eliot LA, Jamali F (2003) Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. Br J Pharmacol 139:945–954CrossRefPubMedPubMedCentral

Schluter KD, Wenzel S (2008) Angiotensin II: a hormone involved in and contributing to pro-hypertrophic cardiac networks and target of anti-hypertrophic cross-talks. Pharmacol Ther 119:311–325CrossRefPubMed

Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T (1995) The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95:651–657CrossRefPubMedPubMedCentral

Takekoshi K, Ishii K, Shibuya S, Kawakami Y, Isobe K, Nakai T (2002) Angiotensin II type 2 receptor counter-regulates type 1 receptor in catecholamine synthesis in cultured porcine adrenal medullary chromaffin cells. Hypertension 39:142–148CrossRefPubMed

Unger T, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, et al (1996) Angiotensin receptors. J Hypertens Suppl 14:S95–S103CrossRefPubMed

Verheggen PW, de Maat MP, Cats VM, Haverkate F, Zwinderman AH, Kluft C et al (1999) Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. Eur Heart J 20:567–574CrossRefPubMed

Wang X, Khaidakov M, Ding Z, Mitra S, Lu J, Liu S et al (2012) Cross-talk between inflammation and angiotensin II: studies based on direct transfection of cardiomyocytes with AT1R and AT2R cDNA. Exp Biol Med 237:1394–1401CrossRef

Wang D, Hu S, Zhu J, Yuan J, Wu J, Zhou A et al (2013) Angiotensin II type 2 receptor correlates with therapeutic effects of losartan in rats with adjuvant-induced arthritis. J Cell Mol Med 17:1577–1587CrossRefPubMedPubMedCentral

Zhu YZ, Chimon GN, Zhu YC, Lu Q, Li B, Hu HZ, et al (2000) Expression of angiotensin II AT2 receptor in the acute phase of stroke in rats. Neuroreport 11:1191–1194CrossRefPubMed

Title: Cardiovascular effect of inflammation and nonsteroidal anti-inflammatory drugs on renin–angiotensin system in experimental arthritis
Authors: Waheed Asghar
Ali Aghazadeh-Habashi
Fakhreddin Jamali
Publication date: 01-10-2017
Publisher: Springer International Publishing
Published in: Inflammopharmacology / Issue 5/2017
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-017-0344-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cardiovascular effect of inflammation and nonsteroidal anti-inflammatory drugs on renin–angiotensin system in experimental arthritis

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2017

Quercetin inhibits gout arthritis in mice: induction of an opioid-dependent regulation of inflammasome

Immunomodulatory basis of antioxidant therapy and its future prospects: an appraisal

Tramadol differentially regulates M1 and M2 macrophages from human umbilical cord blood

Class side effects: decreased pressure in the lower oesophageal and the pyloric sphincters after the administration of dopamine antagonists, neuroleptics, anti-emetics, l-NAME, pentadecapeptide BPC 157 and l-arginine

Yeast RNA extract suppresses human osteoclast resorption in vitro

Predictive value of salivary microRNA-320a, vascular endothelial growth factor receptor 2, CRP and IL-6 in Oral lichen planus progression